All In Biotech

Investigational drug · Phase 3

Purinostat Mesylate

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

7

Any phase or sponsor naming "Purinostat Mesylate"

First trial start

2024

Mar 25, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Purinostat Mesylate", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed or Refractory Multiple Myeloma (RRMM)
  • Recurrent and Refractory Diffuse Large B-cell Lymphoma

Approved drugs for the same conditions: Multiple myeloma · Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Purinostat Mesylate" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Relapsed or Refractory Multiple Myeloma (RRMM)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.